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A B S T R A C T
Purpose: As antiepileptic drugs (AEDs) are known to be associated with alterations in thyroid proﬁles, we
aimed to carry out a meta-analysis to comprehensively assess the effects of AEDs on thyroid hormones in
patients with epilepsy.
Methods: We searched the NCBI (PubMed), ISI Web of Science, EMBASE databases, and Cochrane Library
to identify studies evaluating the association between AED use and thyroid hormone proﬁles in patients
with epilepsy. Fixed or random effects meta-analysis was used to pool results across studies.
Results: In all, 35 studies were included in our analysis. Out of a total of 997 patients in these studies,
epileptic patients receiving AEDs showed an overall signiﬁcant decrease in thyroxin (T4) and free T4
(fT4) and higher levels of thyroid stimulating hormone (TSH) than the controls (T4: standardized mean
difference [SMD] = 1.839, 95% conﬁdence interval [CI], 2.063 to 1.614; fT4: SMD = 1.190, 95% CI,
1.687 to 0.692; TSH: SMD = 0.445, 95% CI, 0.031–0.858). Notably, the use of carbamazepine (CBZ)
suggested a signiﬁcant decrease in triiodothyronine (T3), T4, and fT4; phenytoin (PHT) use showed a
decrease in T4 and fT4; and valproic acid (VPA) use was associated with decreased T4 and increased TSH.
Conclusion: Our study suggests that use of AEDs such as CBZ, PHT, and VPA, was associated with
alteration of thyroid hormones among patients with epilepsy.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is one of the most common neurological conditions,
with about 65 million people affected worldwide [1]. It is a chronic
medical problem that requires long-term or lifelong therapy with
antiepileptic drugs (AEDs), particularly for those patients with
refractory epilepsy [2]. However, prolonged use of AEDs is known
to be associated with adverse effects such as metabolic and organ
toxicity, endocrine disturbance, negative cognitive effects, and
psychiatric problems [3–6], particularly with alterations in thyroid
function in patients with epilepsy [7].
Thyroid hormones are essential for the development and
regulation of the metabolic state of many tissues; thus, dis-
turbances of thyroid function may impede growth and develop-
ment in children and adversely affect endocrine hemostasis in
adults [2]. Oppenheimer and McPherson [8] ﬁrst recognized the* Corresponding author. Tel.: +86 57187784750; fax: +86 57187784750.
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1059-1311/ 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights realteration of thyroid hormones levels in epileptic patients taking
phenytoin (PHT). Thereafter, a number of studies were performed
to evaluate the thyroid proﬁles in patients with epilepsy, but with
inconsistent results. Several studies suggested there was no
change in the thyroid hormone proﬁle among patients taking
AEDs [9–11], while others revealed AEDs might be signiﬁcantly
associated with alteration of thyroid hormones [7,12–15]. With
this background, we aimed to conduct a meta-analysis to study the




A systematic computerized search was conducted according to
the Meta-analysis of Observational Studies in Epidemiology
(MOOSE) guidelines [16]. Three authors (YXZ, CHS, and QLL)
independently screened the NCBI (PubMed), ISI Web of Science,
and EMBASE databases and the Cochrane Library for the periodserved.
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articles were considered. The search terms included ‘‘antic-
onvulsants,’’ ‘‘epilepsy,’’ ‘‘antiepileptic drugs,’’ ‘‘oxcarbazepine
(OXC),’’ ‘‘PHT,’’ ‘‘carbamazepine (CBZ),’’ ‘‘phenobarbital (PB),’’
‘‘lamotrigine (LTG),’’ ‘‘gabapentin (GBP),’’ ‘‘topiramate (TPM),’’
‘‘valproic acid (VPA),’’ ‘‘levetiracetam (LEV),’’ ‘‘thyroid hormones,’’
‘‘triiodothyronine (T3),’’ ‘‘free triiodothyronine (fT3),’’ ‘‘thyroxine
(T4),’’ ‘‘free thyroxine (fT4),’’ and ‘‘thyrotropin (TSH).’’ The above
listed AEDs are the most commonly prescribed and widely used
drugs to treat epilepsy. We retrieved all relevant articles and
searched reference lists to identify as many studies as possible.
2.2. Eligibility criteria
Studies were included if they met the following criteria: (i)
original data from epidemiologic reports with healthy controls; (ii)
cross-sectional, case-control, or cohort studies that evaluated the
association between AEDs and thyroid hormones in patients with
epilepsy; (iii) the exposure was AEDs; (iv) measured thyroid
hormones and expressed the data as means with standard
deviations (SDs); (v) met at least six Newcastle-Ottawa Scale
(NOS) criteria [17]-an eight-item tool with up to nine possible
points, which was developed to assess the quality of observational
studies to be included in systematic reviews and meta-analysis.
2.3. Data extraction
Two authors (ZYX and CHS) evaluated the studies and abstracted
all relevant information independently using a uniﬁed data form.
Divergences were discussed and resolved by a third author (QLL).
The following data were collected from each study: author, year,
country, study design, population, age, gender, AEDs, exposure
duration and measurements of thyroid hormones (T3, fT3, T4, fT4,
and TSH) in patients with epilepsy and healthy controls.
2.4. Data analysis
Considering the different assays in different studies, values of
thyroid hormones were expressed as standardized mean difference
(SMD). Statistical heterogeneity was examined using the I2 statistic;
P < 0.10 was considered signiﬁcant. A value of 0% suggests no
observed heterogeneity, whereas large values indicate increasing
heterogeneity. Thus, P < 0.10 and I2 value >50% indicate signiﬁcant
heterogeneity. When substantial heterogeneity was detected, we
performed the summary estimate on the random effect model using
the DerSimonian and Laird method. Otherwise, the ﬁxed effect
model using the Mantel and Haenszel method was used. To assess
the inﬂuence of individual results on the pooled estimate, we
conducted sensitivity analysis by excluding each study one by one,
and recalculating the combined estimates for the remaining studies.
According to the deﬁnition of children as per The United Nations
Convention on the Rights of the Child, the population was stratiﬁed
into child group (<18 years old) and adult group (>18 years old);
subgroup analysis was thus performed by age.
We carried out Egger’s test and Begg’s test to examine
publication bias, P < 0.05 was considered to represent signiﬁcant
publication bias. All data analysis was performed using STATA/
SE12.0 (Stata, TX, College Station, USA).
3. Results
3.1. Study characteristics
As shown in Fig. 1, our search identiﬁed 35 studies
about AEDs and thyroid hormones [9,10,15,18–49]. The
study details are described in Table 1. Twelve studies[10,20,23,25,27,33,35,38,39,41,42,44] with a total of 997 parti-
cipants described the association between various AEDs and
thyroid hormones; of these, 11 were cross-sectional studies
[10,20,23,27,33,35,38,39,41,42,44], and one was a case-control
study [25]. Four of 12 studies [25,27,33,38] included
only pediatric patients, 3 included only adults [20,23,42], and
5 had a mixed patient population. Moreover, 25 studies
[9,10,15,18,19,21–24,26–34,36–40,43,45] focused on speciﬁc
AEDs, including 17 studies on VPA, 19 on CBZ, and 6 on PHT.
3.2. Use of AEDs and thyroid hormones
Overall, compared to controls, patients with epilepsy
receiving AEDs showed a signiﬁcant decrease in T4 and fT4,
but higher TSH levels (T4: standardized mean difference
[SMD] = 1.839; 95% conﬁdence interval [CI], 2.063 to
1.614; p_heterogeneity = 0.189, I2 = 28.8%; fT4: SMD = 1.190;
1.190; 95% CI, 1.687 to 0.692; p_heterogeneity < 0.001,
I2 = 81.0%; and TSH: SMD = 0.445; 95% CI, 0.031–0.858; p_het-
erogeneity < 0.001, I2 = 83%) (Tables 2–4, Figs. 2–4). The T3
and fT3 levels showed no signiﬁcant differences between
patients and controls. Furthermore, both the Begg’s and
Egger’s tests showed no publication biases; Begg’s test P values
for T3, fT3, T4, fT4, and TSH were 0.592, 0.734, 0.466, 0.175, and
0.161, respectively, and Egger’s test P values for and T3, fT3, T4,
fT4, and TSH were 0.428, 0.577, 0.247, 0.081, and 0.131, respec-
tively. The shape of the Begg’s funnel plot was symmetrical
(Fig. 5).
For the sensitivity analysis, we recalculated the
combined results by excluding one study per iteration; the
results obtained were similar without signiﬁcant ﬂuctuations.
For T4, the study-speciﬁc SMD ranged from a low value of
1.927 (95% CI, 2.172 to 1.681) by omission of the study by
Rozza et al. [42] to a high value of 1.786 (95% CI, 2.051 to
1.521) by omission of the study by Tiihonen et al. [35]. For fT4,
the study-speciﬁc SMD ranged from a low value of 1.344 (95%
CI, 1.670 to 1.019) by omission of the study by Hamed et al.
[20] to a high value of 1.111 (95% CI, 1.627 to 0.594) by
omission of the study by Verrotti et al. [33]. For TSH, the study-
speciﬁc SMD ranged from a low value of 0.338 (95% CI, 0.060 to
0.736) by omission of the study by Rozza et al. [42] to a high
value of 0.579 (95% CI, 0.297–0.860) by omission of the study by
Rao et al. [41].
Subgroup analysis by age (<18 vs. >18 years) showed
signiﬁcant SMDs were found in the child group (T4: SMD = 1.934;
1.934; 95% CI, 2.379 to 1.490; fT4: SMD = 1.450; 95% CI,
1.899 to 1.002; TSH: SMD = 0.635; 95% CI, 0.088–1.182).
3.3. Some speciﬁc AEDs and thyroid hormones
When evaluating the association between CBZ and thyroid
hormones, a signiﬁcant decrease in T3, T4, and fT4 was observed
among patients on CBZ monotherapy (T3: SMD = 0.411; 95% CI,
0.686 to 0.136; T4: SMD = 1.505; 95% CI, 1.852 to 1.158;
fT4: SMD = 1.198; 95% CI, 1.472 to 0.925). However, the SMDs
for fT3 and TSH were insigniﬁcant. Subgroup analysis by age
showed signiﬁcant SMDs for T3, T4, and fT4 in the adult group and
a signiﬁcant decrease in T4 and fT4 in the child group.
Likewise, for patients receiving PHT monotherapy, T4 and fT4
were signiﬁcantly decreased among epileptic patients (T4:
SMD = 1.344; 95% CI, 1.838 to 0.850; fT4: SMD = 0.976;
95% CI, 1.295 to 0.658).
The present study showed a signiﬁcant effect of VPA on serum
T4 and TSH. T4 was signiﬁcantly decreased whereas TSH levels
were increased. (T4: SMD = 0.384; 95% CI, 0.589 to 0.179;
TSH: SMD = 0.942; 95% CI, 0.664–1.220).
Fig. 1. Flow diagram of selection of studies for the meta-analysis.
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While studies evaluating thyroid function status in epileptic
patients suggest that thyroid hormone levels are not directly
related to epilepsy, some changes in thyroid function tests could be
associated with the prescribed AEDs [50]. Our meta-analysis
synthesized all available compatible data reporting the associa-
tions between AEDs and thyroid hormones. Our results showed
signiﬁcant and robust alterations in thyroid proﬁles among
patients receiving AEDs, including decrease of T4 and fT4 and
increase of TSH. However, T3 and fT3 levels seemed unchanged in
patients compared to controls. When we stratiﬁed participants by
age, similar results were obtained in the child group. With respect
to speciﬁc AEDs, it was seen that monotherapy with CBZ and PHT
was signiﬁcantly associated with a reduction of T4 and fT4 levels;
CBZ was also related with lower T3 levels. Furthermore, there was
a signiﬁcant alteration in T4 and TSH levels among epileptic
patients on VPA monotherapy. However, considering the observed
heterogeneity, these ﬁndings should be interpreted with some
caution.
The present study reported signiﬁcantly reduced T4 and fT4
levels along with elevated TSH levels among patients receiving
AEDs. Although it was inconclusive as to whether these changes in
the thyroid proﬁle affected the reference values, the changes
seemed consistent with hypothyroidism [51]. Previous studies
have also found that subclinical hypothyroidism might develop in
epileptic patients during AED therapy [12,18,21,35]. However,patients using AEDs did not show clinical manifestations or signs of
functional hypothyroidism [7]; among children, these changes did
not seem to affect growth or pubertal development [52]. In other
words, clinically signiﬁcant thyroid disorders occur very rarely
[50]. Nevertheless, these results may indicate an increased risk of
hypothyroidism among patients using AEDs. As we know, thyroid
hormones play an important role on physiological process. Once
hypothyroidism appears, it will lead to metabolic syndrome with
multiple system involved [53–57]. Therefore, thyroid hormones
should be taken seriously for patients treated with long-term
AEDs.
As T3 is derived from transformation of T4 in the peripheral
tissues [58], serum T3 and fT3 levels often remain normal even in
severe hypothyroidism and are hence of less sensitivity in
hypothyroidism diagnosis [51]. This may be why no signiﬁcant
alteration in T3 and fT3 was observed in our meta-analysis.
The mechanism of the underlying positive association between
AEDs and thyroid hormones is still unclear. It is known that more
than 99% of circulating thyroid hormones (T3 and T4) are bound to
plasma proteins, and fT3 and fT4 do not appear to interfere with
thyroxin-binding globulin with higher accuracy and sensitivity in
clinical practice. By changing their biosynthesis, secretion,
transport, metabolism, and/or excretion, AEDs can cause several
degrees of impairment in thyroid-hormone homeostasis [2].
According to current literature, it is most likely that AEDs affect
hepatic microsomal enzyme systems and accelerate the metabo-
lism of thyroid hormones. Particularly, liver enzyme-inducing
Table 1










EI-Farahaty RM 2015 Egypt 69/34 15.3 62/41 VPA, CBZ, LTG, TPM, LEV >24 fT4, TSH
Aksoy D 2015 Turkey 79/58 28.8 68/69 VPA, LEV >24 fT3, fT4, TSH
Hamed SA 2015 Egypt 55/30 31.3 85/0 Various AEDs >24 fT4, TSH
Yehia MAE 2012 Egypt 80/50 >18 NA Various AEDs, VPA, CBZ, PHT >6 T3, TSH
Mishra H 2011 India 40/40 NA 56/24 VPA >12 T3, T4, TSH
Yildiz M 2010 Turkey 59/23 7.5 55/27 Various AEDs, CBZ, VPA >6 fT3, fT4, TSH
Castro-Gago M 2007 Spain 57/148 10.5 106/99 CBZ, PB, VPA >12 fT3, fT4
Vainionpaa LK 2004 Finland 78/54 8–18 0/132 CBZ, OXC, VPA >10 fT3, T4, fT4, TSH
Caksen H 2003 Turkey 18/16 11.2 15/19 CBZ >10 T4, fT4, TSH
Caksen H 2002 Turkey 31/22 9.3 29/24 VPA >12 T4, fT4, TSH
Verrotti A 2001 Italy 37/40 8.5 38/39 Various AEDs, CBZ, VPA >24 T3, fT3, T4, fT4, TSH
Eiris-Punal J 1999 Spain 141/148 10.3 157/132 CBZ, VPA, PB >12 T3, T4, fT4
Surks MI 1996 America 19/12 NA 14/17 PHT, CBZ NA fT4, TSH
Tiihonen M 1995 Finland 35/19 33.6 26/28 Various AEDs >3.5 T3, fT3, T4, fT4, TSH
Yuksel A 1993 Turkey 49/12 6.6 31/30 Various AEDs, CBZ, PB, VPA NA T3, fT3, T4, fT4, TSH
Isoja¨rvi JI 1992 Finland 108/28 33.1 97/39 Various AEDs, CBZ, PHT, VPA >12 T3, T4, fT4, TSH
Isoja¨rvi JI 1990 Finland 63/17 32.3 80/0 Various AEDs, CBZ, PHT, VPA >12 T3, T4, fT4, TSH
Rao ML 1987 Germany 27/76 26.8 53/45 Various AEDs NA T3, T4, TSH
Rozza L 1987 Italy 15/37 25.0 52/0 Various AEDs >12 T3, T4, fT4, TSH
Liewendahl K 1985 Finland 50/33 NA NA CBZ, PHT NA T3, fT3, T4, fT4, TSH
Suzuki H 1984 Japan 32/45 34.3 40/37 Various AEDs NA T3, T4, fT4
Franklyn JA 1984 England 31/31 NA NA PHT NA T3, fT3, T4, fT4, TSH
Case-control study
Kim SH 2012 Korea 61/144 9.9 111/94 VPA >12 T3, fT4, TSH
Aggarwal A 2011 India 64/30 8.1 57/37 VPA, CBZ >6 fT3, fT4, TSH
Mahyar A 2011 Iran 30/30 4.8 29/31 Various AEDs >6 T3, T4, TSH
Isoja¨rvi JI 2001 Finland 90/25 32.9 115/0 CBZ, OXC, VPA NA T3, T4, fT4, TSH
Isoja¨rvi JI 1993 Finland 30/19 24.2 24/25 CBZ >12 T3, T4, fT4, TSH
Cohort study
Doneray H 2012 Turkey 28/28 8.2 40/16 VPA 6 T3, fT3, T4, fT4, TSH
Yu L 2006 China 100/40 36 84/56 TPM, CBZ 12 T3, fT3, T4, fT4, TSH
Yuksel A 1993 Turkey 16/13 6.7 13/16 CBZ 12 T3, fT3, T4, fT4, TSH
Isoja¨rvi JI 1989 Finland 40/34 32.8 41/33 CBZ 12 T3, T4, fT4, TSH
VPA, valproate; CBZ, carbamazepine; LTG, lamotrigine; TPM, topiramate; LEV, levetiracetam; fT4, free thyroxine; TSH, thyroid-stimulating hormone; fT3, free
triiodothyronine; AEDs, antiepileptic drugs; NA, not available; PHT, phenytoin; T3, triiodothyronine; T4, thyroxine; PB, phenobarbiturate; OXC, oxcarbazepine.
* These agents were used as monotherapy except for ‘‘Various AEDs’’. ‘‘Various AEDs’’ refers to these which are not detailed explained in literature, including monotherapy,
multidrug therapy or mixed.
Table 2
Subgroup analysis for AED use and serum T4 levels.
Subgroup Sample no Fixed model SMD (95% CI) Random model SMD (95% CI) Heterogeneity test
I2 (%) P
Overall 9 1.839 (2.063, 1.614) 1.858 (2.132, 1.585) 28.8 0.189
Age
Child group 3 1.934 (2.379, 1.490) 1.977 (2.498, 1.456) 20.9 0.282
Carbamazepine 14 1.422 (1.575, 1.270) 1.505 (1.852, 1.158) 79.1 <0.001
Age
Adult group 4 0.853 (1.109, 0.596) 0.970 (1.663, 0.277) 85.9 <0.001
Child group 6 1.611 (1.848, 1.374) 1.604 (1.896, 1.312) 21.9 0.269
Phenytoin 5 1.303 (1.574, 1.031) 1.344 (1.838, 0.850) 69.2 0.011
Valproic acid 11 0.377 (0.533, 0.221) 0.384 (0.589, 0.179) 36.5 0.107
Y.-X. Zhang et al. / Seizure 35 (2016) 72–79 75antiepileptic drugs (LEI AEDs) such as CBZ and PHT induced the
hepatic P450 enzyme system resulting in the reduction of T4 and
fT4, as shown in our study. Moreover, human uridine diphosphate
glucuronosyltransferase (UGT) could also be responsible for
glucuronidation and play a role in metabolism of thyroid
hormones, as high levels of UGT have been observed after AED
exposure in some studies [15,59]. Positive feedback mechanism of
the hypothalamic-pituitary-thyroid axis is then activated by the
decrease in T4 and fT4 levels [60]. Furthermore, another effect of
AEDs on thyroid hormones may be due to the interference ofcompetitive binding of thyroid hormones to thyroxin-binding
globulin [30,32,33,39]. Peripheral conversion of T4 to active T4 also
increased, consequently leading to a decrease of fT4.
As VPA is an established hepatic enzyme inhibitor, it could have
some effect on thyroid hormones. However, the mechanisms of
VPA-induced thyroid dysfunction were not well established [21].
Therefore, it is possible that the mechanism of enzyme induction
was only partially involved. A VPA-mediated decrease in the
concentration of serum T4-binding globulin, displacement from
protein binding sites, and decreased T4 50-deiodinase activity are
Table 3
Subgroup analysis for AED use and serum fT4 levels.
Subgroup Sample no Fixed model SMD (95% CI) Random model SMD (95% CI) Heterogeneity test
I2 (%) P
Overall 9 0.963 (1.173, 0.754) 1.190 (1.687, 0.692) 81.0 <0.001
Age
Child group 3 1.450 (1.899, 1.002) 1.450 (1.899, 1.002) 0.0 0.433
Carbamazepine 18 1.181 (1.315, 1.046) 1.198 (1.472, 0.925) 74.3 <0.001
Age
Adult group 4 0.754 (1.025, 0.482) 0.920 (1.523, 0.317) 77.1 0.004
Child group 9 1.322 (1.510, 1.135) 1.272 (1.564, 0.981) 53.0 0.030
Phenobarbital 3 1.035 (1.381, 0.690) 1.035 (1.381, 0.690) 0.0 0.943
Phenytoin 5 0.957 (1.235, 0.680) 0.976 (1.295, 0.658) 21.4 0.278
Valproic acid 15 0.184 (0.308, 0.061) 0.175 (0.485, 0.135) 82.6 <0.001
Age
Child group 10 0.201 (0.342, 0.059) 0.303 (0.679, 0.074) 84.5 <0.001
Table 4
Subgroup analysis for AED use and serum TSH levels.
Subgroup Sample no Fixed model SMD (95% CI) Random model SMD (95% CI) Heterogeneity test
I2 (%) P
Overall 11 0.303 (0.138, 0.468) 0.445 (0.031, 0.858) 83.0 <0.001
Age
Adult group 3 0.443 (0.186, 0.700) 0.605 (0.062, 1.271) 83.2 0.003
Child group 4 0.564 (0.240, 0.888) 0.635 (0.088, 1.182) 62.3 0.047
Carbamazepine 17 0.178 (0.041, 0.316) 0.207 (0.005, 0.418) 55.9 0.003
Age
Adult group 5 0.077 (0.310, 0.157) 0.059 (0.435, 0.318) 58.9 0.045
Child group 7 0.204 (0.032, 0.440) 0.198 (0.106, 0.501) 37.8 0.140
Phenytoin 6 0.248 (0.011, 0.484) 0.239 (0.053, 0.531) 32.7 0.190
Valproic acid 15 0.920 (0.783, 1.058) 0.942 (0.664, 1.220) 73.5 <0.001
Age
Adult group 3 0.652 (0.366, 0.938) 0.612 (0.202, 1.023) 49.6 0.137
Child group 8 0.808 (0.633, 0.984) 0.788 (0.561, 1.015) 33.8 0.158
Fig. 2. Effects estimates for the association between AED use and serum T4 levels.
Y.-X. Zhang et al. / Seizure 35 (2016) 72–7976
Fig. 3. Effects estimates for the association between AED use and serum fT4 levels.
Fig. 4. Effects estimates for the association between AED use and serum TSH levels.
Y.-X. Zhang et al. / Seizure 35 (2016) 72–79 77all possible explanations [21]. Studies have also shown the
g-aminobutyric acid (GABA)-stimulating properties of VPA, and
GABA may depress the release of somatostatin, which inhibits TSH
secretion [61,62]. Furthermore, VPA may lead to zinc and selenium
deﬁciencies, which have an important role in thyroid hormones
synthesis [62]. In our analysis, CBZ and PHT were indicated to
cause a decrease of T4 and fT4 in the absence of TSH response,possibly owing to the disturbed hypothalamic-pituitary-thyroid
axis or a newly formed balance in tissue level such that even the
decreased hormone levels were satisfactory enough to perform the
necessary metabolic activity [2].
Alterations in thyroid hormone levels seem to be reversible after
cessation of AEDs treatment [2,7,13]. Verrotti et al. [11] showed
normalization of serum T4 and fT4 levels in some CBZ-treated
Fig. 5. Funnel plot of studies on AED use and serum fT4 levels.
Y.-X. Zhang et al. / Seizure 35 (2016) 72–7978children after medication withdrawal 6 months later. Lossius et al.
[63] reported signiﬁcant increases in serum fT4 in patients with
epilepsy 4 months after CBZ withdrawal. Attilakos et al. [64]
suggested that normal serum TSH levels were restored in children
examined at 3 months after VPA withdrawal.
Our study has some limitations. First, all of the included studies
were observational and could not control for all possible con-
founders, which relatively weakened the evidence. Second, our study
did not address or assess whether epilepsy itself played a role in the
alteration of thyroid hormones albeit rare, or the prescribed AEDs
did. Third, the presented heterogeneity was somewhat high despite
stratiﬁcation and subgroup analyses. Finally, many studies reviewed
in our meta-analysis were over 15 years old, and the drugs addressed
were older drugs; the new-generation AEDs were not included in the
analysis. We observed that only few studies relating to AEDs and
thyroid hormones were available in recent literature, of which some
studies did not meet our inclusion criteria and hence, the evidence of
the association between new AEDs and thyroid hormones was rather
limited. Although new-generation AEDs are increasingly featuring in
modern day prescriptions, traditional AEDs are still widely used in
many countries, especially in developing countries. The International
League Against Epilepsy has also recommended the traditional
medications as ﬁrst line drugs [65]. Therefore, we believe that our
results have considerable applications and signiﬁcance in clinical
practice and may provide more insight into epilepsy treatment with
AEDs. Future better designed studies evaluating thyroid function in
the context of serum protein concentrations and liver function are
warranted to more fully explore the AED effects on thyroid hormones
in patients with epilepsy and should focus on more long-term
observation of the interaction between newer generation AEDs and
thyroid hormone proﬁles.
5. Conclusion
Our meta-analysis suggested that use of AEDs such as CBZ, PHT,
and VPA was associated with alteration of thyroid hormones
(decrease of T4 and fT4 and increase of TSH levels) among patients
with epilepsy. Whether these changes are cause for signiﬁcant
clinical concern is yet to be ascertained. Nevertheless, thyroid
function should be paid attention on for patients requiring long-
term AED treatment, especially for those with hypothyroidism
prior to initiation of treatment.
Conﬂicts of interest statement
The authors declare no conﬂict of interest.Acknowledgments
This work was supported by grants from the National Natural
Science Foundation of China (No. 81171227), and the Major
Program of Zhejiang Province Science and Technology Foundation,
China (No. 2012C13018-4).
References
[1] Moshe SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet
2015;385(9971):884–98.
[2] Cansu A. Antiepileptic drugs and hormones in children. Epilepsy Res
2010;89(1):89–95.
[3] Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. CNS Drugs
2013;27(6):435–55.
[4] Jovanovic M, Jocic-Jakubi B, Stevanovic D. Adverse effects of antiepileptic
drugs and quality of life in pediatric epilepsy. Neurol India
2015;63(3):353–9.
[5] Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol
2012;11(9):792–802.
[6] Shen C, Chen F, Zhang Y, Guo Y, Ding M. Association between use of antiepi-
leptic drugs and fracture risk: a systematic review and meta-analysis. Bone
2014;64:246–53.
[7] Svalheim S, Sveberg L, Mochol M, Tauboll E. Interactions between antiepileptic
drugs and hormones. Seizure 2015;28:12–7.
[8] Oppenheimer JH, Fisher LV, Nelson KM, Jailer JW. Depression of the serum
protein-bound iodine level by diphenylhydantion. J Clin Endocrinol Metab
1961;21:252–62.
[9] Caksen H, Dulger H, Cesur Y, Odabas D, Tuncer O, Atas B. No effect of long-term
valproate therapy on thyroid and parathyroid functions in children. Int J
Neurosci 2002;112(11):1371–4.
[10] Isojarvi JI, Pakarinen AJ, Myllyla VV. Thyroid function with antiepileptic drugs.
Epilepsia 1992;33(1):142–8.
[11] Verrotti A, Laus M, Scardapane A, Franzoni E, Chiarelli F. Thyroid hormones in
children with epilepsy during long-term administration of carbamazepine and
valproate. Eur J Endocrinol 2009;160(1):81–6.
[12] Mikati MA, Tarabay H, Khalil A, Rahi AC, El BD, Najjar S. Risk factors for
development of subclinical hypothyroidism during valproic acid therapy. J
Pediatr 2007;151(2):178–81.
[13] Vainionpaa LK, Mikkonen K, Rattya J, Knip M, Pakarinen AJ, Myllyla VV, et al.
Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or
valproate monotherapy and after withdrawal of medication. Epilepsia
2004;45(3):197–203.
[14] Castro-Gago M, Novo-Rodriguez MI, Gomez-Lado C, Rodriguez-Garcia J, Rodri-
guez-Segade S, Eiris-Punal J. Evolution of subclinical hypothyroidism in chil-
dren treated with antiepileptic drugs. Pediatr Neurol 2007;37(6):426–30.
[15] Eirı´s-Pun˜al J, Del RM, Del MC, Lojo-Rocamonde S, Novo-Rodrı´guez I, Castro-
Gago M. Long-term treatment of children with epilepsy with valproate or
carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999;40(12):
1761–6.
[16] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting.
Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.
JAMA 2000;283(15):2008–12.
[17] Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The
Newcastle-Ottawa Scale (NOS)for assessing the qualityofnonrandomisedstudies
in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.
asp. Accessed 10 Jan 2016.
[18] El-Farahaty RM, El-Mitwalli A, Azzam H, Wasel Y, Elrakhawy MM, Hasaneen
BM. Atherosclerotic effects of long-term old and new antiepileptic drugs
monotherapy: a cross-sectional comparative study. J Child Neurol
2015;30(4):451–7.
[19] Aksoy D, Solmaz V, Cevik B, Pekdas E, Kurt S. Serum lipids and thyroid
functions in young epileptic patients undergoing monotherapy with valproate
or levetiracetam. Eur J Gen Med 2015;12:59–63.
[20] Hamed SA, Moussa EM, Tohamy AM, Mohamed KO, Mohamad ME, Sherif TM,
et al. Seminal ﬂuid analysis and testicular volume in adults with epilepsy
receiving valproate. J Clin Neurosci 2015;22(3):508–12.
[21] Kim SH, Chung HR, Kim SH, Kim H, Lim BC, Chae JH, et al. Subclinical
hypothyroidism during valproic acid therapy in children and adolescents with
epilepsy. Neuropediatrics 2012;43(3):135–9.
[22] Doneray H, Kara IS, Karakoc A, Tan H, Orbak Z. Serum thyroid hormone proﬁle
and trace elements in children receiving valproic acid therapy: a longitudinal
and controlled study. J Trace Elem Med Biol 2012;26(4):243–7.
[23] Yehia MAE, Ahmad SF, Abd EAER, Helmy AK, Abd EZMM. Antiepileptic drugs
and risk of subclinical hypothyroidism. Egypt J Neurol Psychiatry Neurosurg
2012;49:131–6.
[24] Aggarwal A, Rastogi N, Mittal H, Chillar N, Patil R. Thyroid hormone levels in
children receiving carbamazepine or valproate. Pediatr Neurol 2011;45(3):
159–62.
[25] Mahyar A, Ayazi P, Dalirani R, Hosseini SM, Kohan MMD. Serum thyroid
hormone levels in epileptic children receiving anticonvulsive drugs. Iran J
Child Neurol 2011;5:21–4.
Y.-X. Zhang et al. / Seizure 35 (2016) 72–79 79[26] Mishra H, Rai YK, Mishra A, Singh V. Valproate-induced subclinical hypothy-
roidism. Indian J Forensic Med Toxicol 2011;5:110–2.
[27] Yildiz M, Simsek G, Uzun H, Uysal S, Sahin S, Balci H. Assessment of low-
density lipoprotein oxidation, paraoxonase activity, and arterial distensibility
in epileptic children who were treated with anti-epileptic drugs. Cardiol
Young 2010;20(5):547–54.
[28] Castro-Gago M, Novo-Rodrı´guez MI, Go´mez-Lado C, Rodrı´guez-Garcı´a J,
Rodrı´guez-Segade S, Eirı´s-Pun˜al J. Evolution of subclinical hypothyroidism
in children treated with antiepileptic drugs. Pediatr Neurol 2007;37(6):
426–30.
[29] Liang Y, Yulan H, Hongbin S, Jie L, Fei X, Xiaoping W. Effects of topiramate and
carbamazepine on thyroid hormone level in adults with epilepsy. Neural
Regen Res 2006;1(8):706–9.
[30] Vainionpa¨a¨ LK, Mikkonen K, Ra¨ttya¨ J, Knip M, Pakarinen AJ, Myllyla¨ VV, et al.
Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or
valproate monotherapy and after withdrawal of medication. Epilepsia
2004;45(3):197–203.
[31] Caksen H, Dulger H, Cesur Y, Atas B, Tuncer O, Odabas D. Evaluation of thyroid
and parathyroid functions in children receiving long-term carbamazepine
therapy. Int J Neurosci 2003;113(9):1213–7.
[32] Isoja¨rvi JI, Turkka J, Pakarinen AJ, Kotila M, Ra¨ttya¨ J, Myllyla¨ VV. Thyroid
function in men taking carbamazepine, oxcarbazepine, or valproate for epi-
lepsy. Epilepsia 2001;42(7):930–4.
[33] Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in
epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol
2001;25(1):43–6.
[34] Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in
patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA
1996;275(19):1495–8.
[35] Tiihonen M, Liewendahl K, Waltimo O, Ojala M, Va¨lima¨ki M. Thyroid status of
patients receiving long-term anticonvulsant therapy assessed by peripheral
parameters: a placebo-controlled thyroxine therapy trial. Epilepsia 1995;36(11):
1118–25.
[36] Yu¨ksel A, Yalc¸in E, Cenani A. Inﬂuence of long-term carbamazepine treatment
on thyroid function. Acta Paediatr Jpn 1993;35(3):229–32.
[37] Isoja¨rvi JI, Airaksinen KE, Repo M, Pakarinen AJ, Salmela P, Myllyla¨ VV.
Carbamazepine, serum thyroid hormones and myocardial function in epileptic
patients. J Neurol Neurosurg Psychiatry 1993;56(6):710–2.
[38] Yu¨ksel A, Kartal A, Cenani A, Yalc¸in E. Serum thyroid hormones and pituitary
response to thyrotropin-releasing hormone in epileptic children receiving
anti-epileptic medication. Acta Paediatr Jpn 1993;35(2):108–12.
[39] Isojarvi JI, Pakarinen AJ, Ylipalosaari PJ, Myllyla VV. Serum hormones in male
epileptic patients receiving anticonvulsant medication. Arch Neurol
1990;47(6):670–6.
[40] Isojarvi JI, Pakarinen AJ, Myllyla VV. Thyroid function in epileptic patients
treated with carbamazepine. Arch Neurol 1989;46(11):1175–8.
[41] Rao ML, Fro¨scher W, Bu¨lau P. Inﬂuence of anticonvulsants and ﬂunarizine on
the metabolism of thyroid hormones: speculation about the possible role of
calmodulin. Clin Neuropharmacol 1987;10(4):356–64.
[42] Rozza L, Marcolla A, Ferrari G. Endocrine function changes in young males
during long-term antiepileptic therapy with phenobarbitone and carbamaze-
pine. Ital J Neurol Sci 1987;8(4):331–6.
[43] Liewendahl K, Tikanoja S, Helenius T, Majuri H. Free thyroxin and free
triiodothyronine as measured by equilibrium dialysis and analog radioimmu-
noassay in serum of patients taking phenytoin and carbamazepine. Clin Chem
1985;31(12):1993–6.[44] Suzuki H, Yamazaki N, Suzuki Y, Hiraiwa M, Shimoda S, Mori K, et al. Lowering
effect of diphenylhydantoin on serum free thyroxine and thyroxine binding
globulin (TBG). Acta Endocrinol 1984;105(4):477–81.
[45] Franklyn JA, Sheppard MC, Ramsden DB. Measurement of free thyroid hor-
mones in patients on long-term phenytoin therapy. Eur J Clin Pharmacol
1984;26(5):633–4.
[46] Liewendahl K, Majuri H, Helenius T. Thyroid function tests in patients on long-
term treatment with various anticonvulsant drugs. Clin Endocrinol
1978;8(3):185–91.
[47] Fichsel H, Kno¨pﬂe G. Effects of anticonvulsant drugs on thyroid hormones in
epileptic children. Epilepsia 1978;19(4):323–36.
[48] Yeo PP, Bates D, Howe JG, Ratcliffe WA, Schardt CW, Heath A, et al. Antic-
onvulsants and thyroid function. Br Med J 1978;1(6127):1581–3.
[49] Liewendahl K, Majuri H. Thyroxine, triiodothyronine, and thyrotropin in
serum during long-term diphenylhydantoin therapy. Scand J Clin Lab Invest
1976;36(2):141–4.
[50] Pennell PB. Hormonal aspects of epilepsy. Neurol Clin 2009;27(4):941–65.
[51] Vaidya B, Pearce SH. Management of hypothyroidism in adults. BMJ
2008;337:a801.
[52] Luef G, Rauchenzauner M. Epilepsy and hormones. A critical review. Epilepsy
Behav 2009;15(1):73–7.
[53] Garduno-Garcia JJ, Alvirde-Garcia U, Lopez-Carrasco G, Padilla Mendoza ME,
Mehta R, Arellano-Campos O, et al. TSH and free thyroxine concentrations are
associated with differing metabolic markers in euthyroid subjects. Eur J
Endocrinol 2010;163(2):273–8.
[54] Thvilum M, Brandt F, Brix TH, Hegedu¨s L. A review of the evidence for and against
increased mortality in hypothyroidism. Nat Rev Endocrinol 2012;8(7):417–24.
[55] Rotondi M, Magri F, Chiovato L. Risk of coronary heart disease and mortality
for adults with subclinical hypothyroidism. JAMA 2010;304:2481 (author
reply 2482).
[56] Setian NS. Hypothyroidism in children: diagnosis and treatment. J Pediatr
2007;83(5):S209–16.
[57] Ganguli M, Burmeister LA, Seaberg EC, Belle S, DeKosky ST. Association
between dementia and elevated TSH: a community-based study. Biol Psychi-
atry 1996;40(8):714–25.
[58] Nandi-Munshi D, Taplin CE. Thyroid-related neurological disorders and com-
plications in children. Pediatr Neurol 2015;52(4):373–82.
[59] Shorvon S. Oxcarbazepine: a review. Seizure 2000;9(2):75–9.
[60] Yilmaz U, Yilmaz TS, Akinci G, Korkmaz HA, Tekgul H. The effect of antiepi-
leptic drugs on thyroid function in children. Seizure 2014;23(1):29–35.
[61] Loscher W, Schmidt D. Increase of human plasma GABA by sodium valproate.
Epilepsia 1980;21(6):611–5.
[62] Castro-Gago M, Novo-Rodrı´guez MI, Go´mez-Lado C, Rodrı´guez-Garcı´a J, Rodrı´-
guez-Segade S, Eirı´s-Pun˜al J. Evolution of subclinical hypothyroidism in chil-
dren treated with antiepileptic drugs. Pediatr Neurol 2007;37(6):426–30.
[63] Lossius MI, Taubøll E, Mowinckel P, Gjerstad L. Reversible effects of antiepi-
leptic drugs on thyroid hormones in men and women with epilepsy: a
prospective randomized double–blind withdrawal study. Epilepsy Behav
2009;16(1):64–8.
[64] Attilakos A, Katsarou E, Prassouli A, Mastroyianni S, Voudris K, Fotinou A, et al.
Thyroid function in children with epilepsy treated with sodium valproate
monotherapy: a prospective study. Clin Neuropharmacol 2009;32(1):32–4.
[65] Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Ka¨lvia¨inen R,
et al. Updated ILAE evidence review of antiepileptic drug efﬁcacy and effec-
tiveness as initial monotherapy for epileptic seizures and syndromes. Epilep-
sia 2013;54(3):551–63.
